INDUSTRY INSIGHT
EYE HEALTH
SPONSORED CONTENT
Associates in Ophthalmology:
First Practice in Western Pennsylvania
to Implant the New AcrySof ® IQ PanOptix ® IOL
PanOptix is already one of the leading presbyopia-correcting
IOLs in more than 70 countries.
It is designed for today’s active lifestyles, from viewing mobile
devices and computer screens to high-quality distance vision in
a range of lighting conditions. The new lens uses ENLIGHTEN®
Optical Technology, a proprietary design that optimizes
intermediate vision without compromising near and distance
vision. Available in spherical and toric designs, PanOptix is
built on Alcon’s proven AcrySof IQ IOL platform that has been
implanted in more than 120 million eyes globally.
“We are proud to bring this new class of IOLs to the largest eye care
market in the world,” said David J. Endicott, Chief Executive Officer of
Alcon. “We are leveraging Alcon’s years of experience with PanOptix
in other countries to provide the best possible training and support
for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract
patients looking to correct their vision at all distances, with the vast
majority of them never needing to wear glasses post-surgery.”
PanOptix delivers an exceptional combination of near,
intermediate and distance vision and substantially reduces
the need for glasses.
n More than ninety-nine percent of PanOptix patients in the
FDA clinical study said they would choose the same lens again.
n
O
n Thursday, September 5, 2019, Associates
in Ophthalmology’s Lisa M. Cibik, MD,
FACS, Director of Cataract Services, was the
first ophthalmologist in Western Pennsylvania
to implant the AcrySof® IQ PanOptix® Trifocal
Intraocular Lens (IOL).
AIO is excited to continue to be the leader in
technology on the western side of Pennsylvania
in the ophthalmology Industry by introducing new
innovative technology to their practice.
Alcon, the global leader in eye care, announced the
Food and Drug Administration (FDA) approval and its
initial commercial launch of AcrySof® IQ PanOptix®
Trifocal Intraocular Lens (IOL), the first and only
trifocal lens for U.S. patients undergoing cataract surgery. PanOptix
is clinically shown to deliver an exceptional combination of near,
intermediate and distance vision while significantly reducing the need
for glasses after surgery.
“My early results with PanOptix have been more
than encouraging!” - Dr. Cibik
More than 4 million cataract surgeries are performed each
year in the U.S., which is projected to increase by more than
16 percent by the end of 2024. The presbyopia-correcting IOL
market is expected to grow 60 percent by the end of 2024.
Cataracts are the most common age-related eye condition
and the leading cause of preventable blindness. Twenty
million people in the U.S. age 40 and older have cataracts.
Cataracts are treated by removing the eye’s cloudy natural
lens and surgically replacing it with an intraocular lens or IOL.
More than 98 percent of cataract surgeries are considered
successful, and patients typically can return to their normal
routines within 24 hours.
Become a PanOptimist and seize life without cataracts with
the PanOptix® Trifocal Lens. To learn more about your cataract
surgery options and if the PanOptix® Lens is right for you, give
us a call to schedule your consultation.
LASER CATARACT SURGERY | DRY EYE | GLAUCOMA | RETINA
MACULAR DEGENERATION | LASIK | DIABETIC EYE CARE
AIOvision.com
888.634.9800
BUTLER | GREENSBURG | KITTANNING | MEADVILLE | MONROEVILLE | MOUNDSVILLE, WV | TITUSVILLE | UNIONTOWN | WEST MIFFLIN | WHEELING, WV
WEST JEFFERSON HILLS
❘
WINTER 2019
17